Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement

Journal of Clinical Epidemiology

Volumn 134, Issue , 2021, Pages 103-112

  Page, Matthew J ^a   McKenzie, Joanne E ^a   Bossuyt, Patrick M ^b   Boutron, Isabelle ^c   Hoffmann, Tammy C ^d   Mulrow, Cynthia D ^e   Shamseer, Larissa ^f   Tetzlaff, Jennifer M ^g   Moher, David ^f,h  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c INSERM   (France)

^d BOND UNIVERSITY   (Australia)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF OTTAWA   (Canada)

^g Evidence Partners Corporation   (Canada)

^h OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Meta analysis; Reporting guidelines; Reproducibility; Systematic reviews; Transparency

Indexed keywords

ADULT; ARTICLE; CHECKLIST; CONVENIENCE SAMPLE; EDITOR; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; PRACTICE GUIDELINE; REPRODUCIBILITY; SYSTEMATIC REVIEW; CONSENSUS; EVIDENCE BASED MEDICINE; PROTOCOL COMPLIANCE; QUESTIONNAIRE; RESEARCH;

CONSENSUS; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HUMANS; RESEARCH REPORT; SURVEYS AND QUESTIONNAIRES; SYSTEMATIC REVIEWS AS TOPIC;

EID: 85101868683     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2021.02.003     Document Type: Article

References (55)

1. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
2. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62 (2009), 1006–1012.
3. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151 (2009), 264–269 W64.
4. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine /Public Library of Science, 6, 2009, e1000097.
5. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8 (2010), 336–341.
6. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med 3 (2009), e123–e130.
7. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, PRISMA, Reprint–preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Phys Ther 89 (2009), 873–880.
8. Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gotzsche, PC, Ioannidis, JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62 (2009), e1–34.
9. Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gotzsche, PC, Ioannidis, JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ, 339, 2009, b2700.
10. Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gotzsche, PC, Ioannidis, JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151 (2009), W65–W94.
11. Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gotzsche, PC, Ioannidis, JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine /Public Library of Science, 6, 2009, e1000100.
12. Liberati, A, Altman, DG, Tetzlaff, J, Mulrow, C, Gøtzsche, PC, Ioannidis, JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. Italian J Public Health 6 (2009), 354–391.
13. Page, MJ, Moher, D., Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review. Systematic rev., 6, 2017, 263.
14. Moher, D, Schulz, KF, Simera, I, Altman, DG., Guidance for developers of health research reporting guidelines. PLoS medicine, 7, 2010, e1000217.
15. Schulz, KF, Altman, DG, 2010, Moher D.CONSORT, statement: updated guidelines for reporting parallel group randomised trials. BMJ, 340, 2010, c332.
16. Campbell, MK, Piaggio, G, Elbourne, DR, Altman, DG., Consort 2010 statement: extension to cluster randomised trials. BMJ, 345, 2012, e5661.
17. Bossuyt, PM, Reitsma, JB, Bruns, DE, Gatsonis, CA, Glasziou, PP, Irwig, L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ, 351, 2015, h5527.
18. Boutron, I, Altman, DG, Moher, D, Schulz, KF, Ravaud, P, Group, for the Consort N.P.T., Consort statement for randomized trials of nonpharmacologic treatments: a 2017 update and a consort extension for nonpharmacologic trial abstracts. Ann Intern Med 167:1 (2017), 40–47.
19. Page MJ. Update of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement (registered in the EQUATOR Network library for health research reporting on 13 December 2017) [https://www.equator-network.org/library/reporting-guidelines-under-development/reporting-guidelines-under-development-for-systematic-reviews/#86].
20. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann T, Mulrow CM, et al. Updating the PRISMA reporting guideline for systematic reviews and meta-analyses. Retrieved from osf.io/2v7mk. 10.17605/OSF.IO/XFG5N. 2018, February 14.
21. Page, MJ, Shamseer, L, Altman, DG, Tetzlaff, J, Sampson, M, Tricco, AC, et al. Epidemiology and reporting characteristics of systematic reviews of biomedical research: a cross-sectional study. PLoS medicine, 13, 2016, e1002028.
22. Page, MJ, Altman, DG, Shamseer, L, McKenzie, JE, Ahmadzai, N, Wolfe, D, et al. Reproducible research practices are underused in systematic reviews of biomedical interventions. J Clin Epidemiol 94 (2018), 8–18.
23. Page, MJ, Altman, DG, McKenzie, JE, Shamseer, L, Ahmadzai, N, Wolfe, D, et al. Flaws in the application and interpretation of statistical analyses in systematic reviews of therapeutic interventions were common: a cross-sectional analysis. J Clin Epidemiol 95 (2018), 7–18.
24. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, T, Mulrow, CD, et al. Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines. J Clin Epidemiol 118 (2020), 60–68.
25. Moher, D, Shamseer, L, Clarke, M, Ghersi, D, Liberati, A, Petticrew, M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015. statement. Systematic rev., 4, 2015, 1.
26. Shamseer, L, Moher, D, Clarke, M, Ghersi, D, Liberati, A, Petticrew, M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 349, 2015, g7647.
27. Welch, V, Petticrew, M, Tugwell, P, Moher, D, O'Neill, J, Waters, E, et al. PRISMA-Equity 2012 extension: reporting guidelines for systematic reviews with a focus on health equity. PLoS medicine, 9, 2012, e1001333.
28. Beller, EM, Glasziou, PP, Altman, DG, Hopewell, S, Bastian, H, Chalmers, I, et al. PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts. PLoS medicine., 10, 2013, e1001419.
29. Hutton, B, Salanti, G, Caldwell, DM, Chaimani, A, Schmid, CH, Cameron, C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162 (2015), 777–784.
30. Stewart, LA, Clarke, M, Rovers, M, Riley, RD, Simmonds, M, Stewart, G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA 313 (2015), 1657–1665.
31. Zorzela, L, Loke, YK, Ioannidis, JP, Golder, S, Santaguida, P, Altman, DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. BMJ, 352, 2016, i157.
32. Guise, JM, Butler, ME, Chang, C, Viswanathan, M, Pigott, T, Tugwell, P, et al. AHRQ series on complex intervention systematic reviews - paper 6: PRISMA-CI extension statement & checklist. J Clin Epidemiol. 90 (2017), 43–50.
33. McInnes, MF, Moher, D, Thombs, BD, McGrath, TA, Bossuyt, PM, Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA statement. JAMA 319 (2018), 388–396.
34. Tricco, AC, Lillie, E, Zarin, W, O'Brien, KK, Colquhoun, H, Levac, D, et al. PRISMA extension for scoping reviews (PRISMA-SCR): checklist and explanation. Ann Intern Med 169 (2018), 467–473.
35. Kapadia, MZ, Askie, L, Hartling, L, Contopoulos-Ioannidis, D, Bhutta, ZA, Soll, R, et al. PRISMA-Children (C) and PRISMA-Protocol for Children (P-C) Extensions: a study protocol for the development of guidelines for the conduct and reporting of systematic reviews and meta-analyses of newborn and child health research. BMJ Open, 6, 2016, e010270.
36. Rethlefsen M, Koffel J, Kirtley S. PRISMA-Search: guidelines for reporting systematic review literature searches (registered 17 February 2016) http://www.equator-network.org/library/reporting-guidelines-under-development/#57 [accessed 16 August 2017].
37. Bian Z. Preferred Reporting Items for Systematic Review and Meta-Analyses of traditional Chinese medicine: the PRISMA-TCM Statement (registered 18 August 2016) http://www.equator-network.org/library/reporting-guidelines-under-development/#65 [accessed 16 August 2017].
38. Stevens A. PRISMA-RR 2017: an extension to PRISMA for rapid reviews (registered 4 November 2015) http://www.equator-network.org/library/reporting-guidelines-under-development/#51 [accessed 16 August 2018].
39. Cohen, JF, Korevaar, DA, Gatsonis, CA, Glasziou, PP, Hooft, L, Moher, D, et al. STARD for Abstracts: essential items for reporting diagnostic accuracy studies in journal or conference abstracts. BMJ, 358, 2017, j3751.
40. Mayo-Wilson, E, Li, T, Fusco, N, Dickersin, K., Practical guidance for using multiple data sources in systematic reviews and meta-analyses (with examples from the MUDS study). Research synthesis methods 9 (2018), 2–12.
41. Stovold, E, Beecher, D, Foxlee, R, Noel-Storr, A., Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Systematic rev, 3, 2014, 54.
42. Haddaway, NR, Macura, B, Whaley, P, Pullin, AS., ROSES RepOrting standards for Systematic Evidence Syntheses: pro forma, flow-diagram and descriptive summary of the plan and conduct of environmental systematic reviews and systematic maps. Environmental Evidence, 7, 2018, 7.
43. Boers, M., Graphics and statistics for cardiology: designing effective tables for presentation and publication. Heart 104 (2018), 192–200.
44. Page MJ, McKenzie JE, Bossuyt P, Boutron I, Hoffmann T, Mulrow CD, et al. Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2019 Statement: updated guidelines for reporting systematic reviews and meta-analyses. In: Abstracts of the 26th Cochrane Colloquium, Santiago, Chile. Cochrane Database of Systematic Reviews. 2019(1 Suppl 1):102-3. https://doi.org/10.1002/14651858.CD201901. Video available at https://www.youtube.com/watch?v=Y-fu00PSm9o.
45. Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. MetaArXiv, 2020 September 14. 10.31222/osf.io/v7gm2.
46. von Elm, E, Altman, DG, Egger, M, Pocock, SJ, Gotzsche, PC, Vandenbroucke, JP., Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335 (2007), 806–808.
47. Collins, GS, Reitsma, JB, Altman, DG, Moons, KG., Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 162 (2015), 55–63.
48. Page, MJ, Moher, D, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. MetaArXiv, 2020 September 14. 10.31222/osf.io/gwdhk.
49. Barnes, C, Boutron, I, Giraudeau, B, Porcher, R, Altman, DG, Ravaud, P., Impact of an online writing aid tool for writing a randomized trial report: the COBWEB (Consort-based WEB tool) randomized controlled trial. BMC medicine, 13, 2015, 221.
50. Chauvin, A, Ravaud, P, Moher, D, Schriger, D, Hopewell, S, Shanahan, D, et al. Accuracy in detecting inadequate research reporting by early career peer reviewers using an online CONSORT-based peer-review tool (COBPeer) versus the usual peer-review process: a cross-sectional diagnostic study. BMC medicine, 17, 2019, 205.
51. Marquez, C, Johnson, AM, Jassemi, S, Park, J, Moore, JE, Blaine, C, et al. Enhancing the uptake of systematic reviews of effects: what is the best format for health care managers and policy-makers? A mixed-methods study. Implementation science: IS, 13, 2018, 84.
52. Schlüssel MM. Strengthening the methodology of reporting guidelines: mapping the landscape, updating development guidance and creating a methodological quality badging system. https://osf.io/ebguf. 2020.
53. Korevaar, DA, Cohen, JF, Reitsma, JB, Bruns, DE, Gatsonis, CA, Glasziou, PP, et al. Updating standards for reporting diagnostic accuracy: the development of STARD 2015. Research integrity and peer review, 1, 2016, 7.
54. Dimairo, M, Coates, E, Pallmann, P, Todd, S, Julious, SA, Jaki, T, et al. Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC medicine, 16, 2018, 210.
55. Sones, W, Julious, SA, Rothwell, JC, Ramsay, CR, Hampson, LV, Emsley, R, et al. Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial - the development of the DELTA(2) guidance. Trials, 19, 2018, 542.